CoChat
Sign Up
Cited by 33Schizophrenia research and treatmentElectroconvulsive Therapy StudiesNeurological and metabolic disorders

The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.

Is Tardive Dyskinesia a Unique Disorder?

Marsden, C. D.·1985·Psychopharmacology Supplementum
DOI 10.1007/978-3-642-70140-5_8
Open this paper in CoChat — free account

Abstract

The role of neuroleptics in causing the tardive dyskinesia syndrome is controversial. To properly assess the contribution of drugs as the etiology of dyskinesias, the effects of aging, the natural history of psychosis, and characteristics of spontaneous dyskinesias must be considered. Though the buccolinguo-masticatory triad is seen more often in tardive than in spontaneous dyskinesias, these two disorders have many symptoms in common. Other dyskinesias, such as idiopathic and tardive dystonia or tardive Tourette's syndrome and dyskinesias in untreated schizophrenia, are poorly understood. Chronic neuroleptic treatment may only precipitate TD in those already predisposed to develop such movement disorders. Tardive dyskinesia is not a unique movement disorder, but rather spans several clinical and epidemiological phenomena which must be considered in a balanced evaluation of how much of the permanent dyskinesias should be attributed to neuroleptic drugs.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-3-642-70140-5_8

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • An early review of studies found that it took 2-5 years for 60%-90% of symptoms of TD to resolve following antipsychotic cessation.

    “An early review of studies found that it took 2–5 years for 60%–90% of symptoms of TD to resolve following antipsychotic cessation (supplementary table S1).76”

    From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [76]

  • TD can resolve when antipsychotics are discontinued but this process might, in some cases, take years and may be irreversible in some patients.

    “This suggests that TD (along with, presumably, dopaminergic hypersensitivity) can resolve when antipsychotics are discontinued but this process might, in some cases, take years75,76 and may be irreversible in some patients.75”

    From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [76]

  • There is likely considerable interindividual variability in the tapering process, with patients able to tolerate greatly varying rates of reduction; some long-term treated patients may need longer periods, and some first-episode patients or those treated for briefer periods may tolerate shorter tapering periods.

    “There is likely to be considerable interindividual variability in this process, with patients able to tolerate greatly varying rates of reduction: given the data on time for TD to resolve, some long-term treated patients may need longer periods, and some first-episode patients or those treated for briefer periods may tolerate shorter tapering periods.75,76,78,101”

    From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [76]

Citations

Cites

Flagged first, then by citations

1 of the 10 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Kahlbaum KL (1973) Catatonia. Johns Hopkins University Press, Baltimore
  2. Kraepelin EL (1907) Die Psychiatrie. 7th ed. English edition: McMillan, London
  3. Kraepelin EL (1919) Textbook of psychiatry, vol 3, dementia praecox, Livingstone, Edinburgh, part 2

Cited by

Sorted by citations

Related

Metadata

Authors
Marsden, C. D.
Affiliations
King's College London (GB)
Corresponding author
Marsden, C. D.
Venue
Psychopharmacology Supplementum
Publisher
Springer Berlin Heidelberg
Published
1985
Volume
2
Pages
64-71
ISSN
0931-6795 (ISSN-L)
DOI
10.1007/978-3-642-70140-5_8
OpenAlex
W66854059
Cited by
33
References
10
Citations by year
2025: 1 · 2021: 2 · 2018: 1 · 2015: 1 · 2012: 1
FWCI
6.42
Type
book chapter
Language
en
Open access
closed
Locations
  • Psychopharmacology series (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Health Sciences › Medicine › Clinical Neurology › Neurological and metabolic disorders
Keywords
tardive dyskinesia, antipsychotic drugs, drug-induced movement disorders, tardive dystonia, untreated schizophrenia, aging, psychosis
MeSH terms
Diagnosis, Differential, Dyskinesia, Drug-Induced, Humans, Schizophrenia, Schizophrenic Psychology, Stereotyped Behavior, Antipsychotic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review